News room
Technophage Recognized as PME Líder 2025
Once more we are thrilled to announce that Technophage has been recognized by IAPMEI, I.P. – Agência para a Competitividade e Inovação with the PME...
TP-102 Phase 2b End of Study Marks Key Step Toward Phase 3 Development
We are pleased to share that last Friday marked an important milestone for Technophage with the End of Study of the TP-102 Phase 2b clinical trial....
Technophage Awarded PME Excelência 2024 Status
We are proud to share that Technophage has been awarded the 'PME Excelência 2024' status. This recognition highlights companies with strong...
Technophage Reaches Last Patient First Visit in REVERSE 2 Trial for TP-102
We are thrilled to share a major milestone in Technophage’s TP-102 clinical trial – REVERSE 2 – with the Last Patient First Visit (LPFV) now...
Technophage Initiates Phase 1b/2a Clinical Trial of TZ-161 for Acute Spinal Cord Injury
Technophage S.A., a clinical-stage biopharmaceutical company focused on developing innovative therapies for areas of unmet medical need, today...